METHODS: A 69-year-old woman with a BRCA1 mutated EOC relapsed five months after starting olaparib maintenance following neoadjuvant chemotherapy and interval debulking surgery. Although the platinum-free interval was within six months, secondary cytoreductive surgery was performed because the tumor was locoregional. Following two cycles of weekly nedaplatin, niraparib induced a complete response, and the patient maintained a progression-free status for 15 months.
CONCLUSIONS: Even with short-term progression on PARP-I, local control combined with different platinum agents and PARP-I can be used to achieve good responses.
方法:一名患有BRCA1突变EOC的69岁女性,在新辅助化疗和间隔减积手术后开始奥拉帕尼维持治疗5个月后复发。尽管无铂间隔在六个月内,因为肿瘤是局部的,所以进行了二次细胞减灭术.在每周两次奈达铂治疗后,尼拉帕利诱导完全反应,患者维持无进展状态15个月.
结论:即使PARP-I有短期进展,局部控制联合不同铂类药物和PARP-I可以达到良好的反应。